Biodistribution and Toxicity Assessment of Intratumorally Injected Arginine-Glycine-aspartic Acid Peptide Conjugated to CdSe/ZnS Quantum Dots in Mice Bearing Pancreatic Neoplasm

Ming-Ming Li,Jia Cao,Jia-Chun Yang,Yu-Jie Shen,Xiao-Lei Cai,Yuan-Wen Chen,Chun-Ying Qu,Yi Zhang,Feng Shen,Min Zhou,Lei-Ming Xu

DOI: https://doi.org/10.1016/j.cbi.2018.06.014

IF: 5.168

2018-01-01

Chemico-Biological Interactions

Abstract:Quantum dots (QDs) conjugated with arginine-glycine-aspartic acid (RGD) peptides (which are integrin antagonists) are novel nanomaterials with the unique optical property of high molar extinction coefficient, and they have potential utility as photosensitizers in photodynamic therapy (PDT). Our group previously demonstrated significant benefits of using PDT with QD-RGD on pancreatic tumor cells. This study aimed to evaluate the biodistribution and toxicity of QD-RGD in mice prior to in vivo application. Mice with pancreatic neoplasms were intratumorally injected with varying doses of QD-RGD, and the biodistribution 0-24 h post injection was compared to that in control mice (intravenously injected with unconjugated QD). Various tissue samples were collected for toxicity analyses, which included inductively coupled plasma mass spectrometry (ICP-MS) to assess Cd2+ concentrations and hematoxylin-eosin staining for histopathological examination. Fluorescent imaging revealed relatively sufficient radiant efficiency in mice under specific conditions. The ICP-MS and HE data showed no significant signs of necrosis due to Cd2+ release by QDs. The mice survived well and had no apparent weakness or weight loss during the 4 weeks post injection. These findings provide novel insights into the biodistribution of QD-RGD and encourage profound in vivo studies regardless of safety concerns. These findings alleviate safety concerns and provide novel insights into the biodistribution of QD-RGD, offering a solid foundation for comprehensive in vivo studies.